Compare ZURA & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZURA | REFI |
|---|---|---|
| Founded | 2022 | 2021 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.8M | 255.6M |
| IPO Year | N/A | 2021 |
| Metric | ZURA | REFI |
|---|---|---|
| Price | $5.38 | $12.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $11.78 | N/A |
| AVG Volume (30 Days) | ★ 565.6K | 140.9K |
| Earning Date | 03-19-2026 | 03-12-2026 |
| Dividend Yield | N/A | ★ 15.65% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $48,857,628.00 |
| Revenue This Year | N/A | $15.98 |
| Revenue Next Year | N/A | $1.33 |
| P/E Ratio | ★ N/A | $7.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $11.62 |
| 52 Week High | $7.25 | $15.49 |
| Indicator | ZURA | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 36.04 | 43.76 |
| Support Level | $3.33 | $11.84 |
| Resistance Level | $5.75 | $12.46 |
| Average True Range (ATR) | 0.50 | 0.26 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 2.99 | 8.86 |
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.